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Graphical abstract 
 
 
 
 
Highlights: 
 We unravelled the full potential of chromogenic substrates for optical detection biomarkers in 
microfluidic devices 
 Commercial chromogenic substrate formulations are suboptimum tuned to meso-scale systems 
 We demonstrated optical detection of clinically relevant biomarkers in microfluidics devices 
with optimised OPD:H2O2 formulation 
 Assay times and lower limit of detection for PSA and IL-1 reduced by one order of magnitude 
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Abstract: One of the biggest challenges in miniaturization of optical immunoassays is the short light path 
distance of microchannels/microcapillaries. Protein biomarkers are often presented in circulating blood in 
the picomolar-femtomolar range, requiring exceptional levels of sensitivity that cannot be met with 
traditional chromogenic substrates and without sophisticated, bulky detection systems. This study 
discloses an effective strategy for increasing the sensitivity and shorten the total test time for sandwich 
ELISAs in microfluidic devices optically interrogated, based on enhancing enzymatic amplification. We 
found that activity of Horseradish Peroxidase (HRP) in mesofluidic systems is highly limited by diffusion, 
therefore increasing the concentration of enzymatic substrate in these systems does not translate into an 
enhancement in enzymatic conversation. The opposite happens in microfluidic systems due to short 
diffusion distances, however increased concentration of the second enzymatic substrate, hydrogen 
peroxide (H2O2), leads to enzyme inhibition as herein reported. Consequently, we found that the molar 
ratio of o-phenylenediamine (OPD) to hydrogen peroxide from commercially substrate formulations is 
not suitable for miniaturized system. Sandwich ELISA quantitation of a cancer biomarker PSA and human 
cytokine IL-1 in fluoropolymer microfluidic strips revealed over one order of magnitude increase in 
sensitivity and 10-fold decrease in incubation time by simply changing the molar ratio of OPD:H2O2 from 
1:3 to 1:1 and increasing OPD concentration from 1 to 4 mg/ml. This enhancement in enzymatic 
amplification offers finally the sensitivity required for optical interrogation of novel portable and 
affordable microfluidic devices with inexpensive and ubiquitous smartphones and flatbed scanners. 
 
Keywords: microfluidics, colorimetric, immunoassay, biomarker, enzymatic amplification, HRP, OPD 
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1. INTRODUCTION 
The development of affordable diagnostic test is highly dependent on the use of low-cost detection 
systems, which often means lower signal resolution and poor assay performance. Creating tests capable 
of quantifying biomarkers at very low concentrations whilst maintaining a reduced cost for the test is a 
fundamental condition for point-of-care (POC) diagnostics industry. Assay miniaturization is one of the 
main trends in clinical diagnostics, and several studies have succeed in applying microfluidic devices in a 
range of shapes and detection methods[1–4] for rapid and sensitive detection of different analytes for 
different clinical situations. This includes infectious diseases,[5,6] biomarkers[7] and food allergens[8] to 
name a few, and typically requires the ability of detecting molecules in the nanomolar to picomolar 
concentration range. This is achieved with the use of expensive detection equipment that is often 
incompatible with the user requirements and product specifications for POC tests. An alternative approach 
that surprisingly remains underexplored is to further potential the natural “amplification” capability of 
well-established enzymes[9] to yield rapid and sensitive detection, using inexpensive and widespread 
chromogenic colorimetric substrates and low-cost optoelectronic components,[10] such as flatbed 
scanners,[11] smartphones[12],[13] and other cost effective readout systems.[14] 
It appears established within the scientific community that high-sensitivity detection can only be 
achieved with direct fluorescence labelling of molecules, since fluorophores provide high amplification 
power required for detecting very low concentrations of molecules in biological sample. However 
fluorescence has main drawbacks in respect to microfluidic POC testing, such as scattering noise, cross-
talks, misalignment, autofluorescence of substrate, and low collection efficiency.[15] 
Our research group has pioneered the application of an extruded, low-cost microfluidic material to 
immunoassays, based on a fluoropolymer Microcapillary Film (MCF),[16] as shown in Fig. 1B. The 
hydrophobic surface of Teflon-FEP is ideal for immobilizing immunoassay reagents in the inner surface 
of the microcapillaries, whereas the refractive index of material similar to that of water allows unique 
signal-to-noise ratios which favors simple optical detection. This is due to minimal optical refraction at 
the water:capillary wall interface and thus no distortion is caused by the capillaries when filled with 
colored aqueous solutions.[16] We have recently reported a 13 min colorimetric prostate cancer antigen 
(PSA) sandwich assay from whole blood with limit of detection below 1 ng/ml using both a flatbed scanner 
and a smartphone.[13,17] Also, we have recently reported a multiplex femtomolar detection of four 
cytokines (IL-1β, IL-6, IL-12 and TNF-α) using colorimetric detection with a flatbed scanner.[18] We 
believe enzymatic amplification combined with unique characteristics of microfluidic devices is the key 
to high-sensitivity POC test with low-cost, modest-performance optoelectronic components.[19] 
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In this study we present for the first time our strategy for enhancing enzymatic amplification in 
colorimetric immunoassay which used optimized Horseradish Peroxidase (HRP) conversion of a very 
popular chromogenic substrate, o-phenylenediamine dihydrochloride (OPD), adapted to microscale 
enzymatic conversion and enzyme-linked immunosorbent assay (ELISA) detection. HRP is one of the 
most popular enzymes in ELISA technique for presenting a very high turnover number. We noticed 
the composition of commercial OPD:H2O2 substrate is adapted to standard laboratory systems 
controlled by diffusion, such as microwell plates,[20–22] where HRP performance is sub-optimum. 
Miniaturization of ELISA in our fluoropolymer microfluidic devices allowed overcoming diffusion 
limitations, similar to what happens when enzymes are in solution (Fig. 1A). Consequently, HRP 
enzyme can be used to yield much higher conversion rates of OPD and consequently achieve 
significant colorimetric signals with shorter incubation times. This resulted in a very large 
improvement in both assay speed and assay sensitivity, as supported by our experience with PSA and 
human IL-1β assay development. PSA is the mostly widely used prostate cancer biomarker with a 
clinical threshold value of 4 ng/ml, above which the patients need to proceed for biopsy examination. 
PSA values of 0.4 to 2 ng/ml are the clinical thresholds for disease monitorization after radical 
prostatectomy and radiotherapy.[23–29] The cytokines clinical threshold values are in the order of 
pg/ml concentrations[30], which means bioassay devices need to be able to quantitate this 
concentration range in order to perform e.g. early detection of sepsis [31,32] and infectious 
diseases.[33,34]  
2. MATERIALS AND METHODS 
2.1 Reagents and Materials 
2,3-diaminophenazine (DAP) and SIGMAFAST™ OPD (o-phenylenediamine) tablets were supplied 
from Sigma Aldrich Ltd (Dorset, UK). A Human kallikrein 3/ Prostate Specific Antigen (PSA) ELISA kit 
was purchased from R&D Systems (Minneapolis, USA; cat nº DY1344). The kit contained a monoclonal 
mouse Human Kallikrein 3/PSA antibody (capture antibody or CapAb), a Human Kallikrein 3/PSA 
polyclonal biotinylated antibody (detection antibody or DetAb) and recombinant Human Kallikrein 3/PSA 
(standard). Human cytokines reagents were purchased from eBiosciences (Hatfield, UK): IL-1β (cat no: 
human recombinant protein #14-8018; Anti-Human IL-1β biotin #13-7016;Anti-Human IL-1β purified 
#14-7018); IL-12p70 (cat no: human recombinant protein #14-8129; Anti-Human IL-12p70 biotin #13-
7129; Anti-Human IL-12p70 purified #14-7128); IL-6 (cat no: human recombinant protein #14-8069; 
Anti-Human IL-6 biotin #13-7068; Anti-Human IL-6 purified #14-7069); and Tumor Necrosis Factor-α 
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(TNFα) (cat no: human recombinant protein #14-8329; Anti-Human TNFα biotin #13-7349; Anti-Human 
TNFα purified #14-7348). ExtrAvidin-Peroxidase (cat. no E2886) was sourced from Sigma Aldrich Ltd 
(Dorset, UK) and High Sensitivity Streptavidin-HRP was supplied by Thermo Scientific (Lutterworth, 
UK; cat no 21130) and used for enzyme detection for IL-1β assay.  Phosphate buffered solution (PBS, 
Sigma Aldrich, Dorset, UK; cat. no P5368-10PAK), pH 7.4, 10mM was used as IA buffer. The diluent 
and blocking solution consisted either of SuperBlock (Thermo Fisher Scientific, Loughborough, UK; cat. 
no 37515) or 1 to 3% w/v protease-free albumin from bovine serum (BSA, Sigma Aldrich, Dorset, UK; 
cat no A3858) diluted in PBS buffer. For washings, PBS with 0.05% v/v of Tween-20 (Sigma-Aldrich, 
Dorset, UK; cat no P9416-50ML) was used. Nunc maxisorp ELISA 96-well Microtiter Plates (MTP) were 
sourced from Sigma Aldrich (Dorset, UK). The MCF was supplied by Lamina Dielectrics Ltd 
(Billingshurts, West Sussex, UK). 
2.2 Microfluidic strips 
The miniaturized platform consisted of a 10 bore, 200 µm internal diameter fluoropolymer MCF[16] 
(Fig.1B) produced by a novel continuous melt-extrusion process,[35] which due to its geometrical shape 
and optical properties can be easily integrated with low-cost and easy access readout system, such as a 
flatbed scanner. 
2.3 Lower optical detection limit 
For comparison of MCF and MTP lower detection limit, different concentrations of DAP were 
detected in the MCF using a flatbed scanner (HP ScanJet G4050) and in the 96 well plate using a 
Microplate Reader (Epoch, Biotek). A stock solution of 1 mg/ml of DAP (Sigma-Aldrich, Dorset, UK; 
cat. no. E2886) was prepared in dimethyl sulfoxide (DMSO) (Sigma-Aldrich, Dorset, UK; cat. no.D8418) 
and a 1:2 dilution series in PBS was made to complete the calibration curves. Absorbance values were 
calculated by determining the grey scale peak height for each individual microcapillary in the MCF using 
ImageJ software (NIH, Maryland, USA), or using the embedded Gen5 data analysis software for microtiter 
plate (Epoch, Biotek). 
2.4 Chromogenic substrate conversion  
In order to find the best combination of OPD:H2O2 concentration, stock solutions of 4 mg/ml of both 
OPD and H2O2 concentrations were prepared in deionized water and diluted in a 1:2 dilution series. The 
solutions were placed in a Nunc MaxiSorp ELISA 96-well microwell plate using a matrix arrangement 
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(OPD and H2O2 concentrations varied along the rows and columns, respectively). EA-HRP was used in 
solution in a concentration of 0.0156 µg/ml.  
The initial enzymatic rates of HRP conversion of OPD to DAP were determined by testing different 
concentrations of OPD and HRP using both immobilized and solubilized enzyme. A start solution with 1 
µg/ml of EA-HRP was immobilized by overnight incubation in the first well of the first column of the 
microtiter plate, followed by 1:2 dilution solutions in each column. Then, 1:2 dilutions of 1 mg/ml of each 
substrate (OPD and H2O2) were prepared and placed along the rows in the microtiter plate, reading 
immediately the absorbance values with a microtiter plate reader. To understand the role of diffusion, the 
procedure was repeated with the enzyme in solution, by spiking each well with the same quantity of EA-
HRP. 
2.5 Full response curves 
Full response curves for PSA and IL-1β were performed in the MCF using different concentrations 
and molar ratios of OPD:H2O2. To obtain the calibration curves, two 30 cm length MCF strips (strips #1 
and #2) were coated with 10 μg/ml of human kallikrein 3/PSA capture antibody (CapAb) diluted in 
phosphate-buffered saline or 20 µg/ml of Anti-Human IL-1β purified (strips #3 and #4) using a single 
syringe attached with silicone tube for fluid handling (Fig.1C). The MCF strips were incubated for 2 hours 
at room temperature (20°C) to allow the CapAb to adsorb on the microcapillary surface, and subsequently 
blocked with 1% BSA (strips #1, #2 and #3) or superblock blocking buffer (strip #4), for 2 hours at room 
temperature  The strips were washed using PBS with 0.05% (v/v) of Tween-20. Each MCF coated strip 
was trimmed into 30 mm long test strips, and each strip incubated with a serial dilution 0-60 ng/ml of PSA 
(recombinant human kallikrein 3/PSA) for 20 min (strip #1 and #2) or a serial dilution 0-1 ng/ml of IL-1β 
for 30 min (strip #3) and 0-5 ng/ml in strip #4. Then, 2 µg/ml of human kallikrein 3/PSA polyclonal 
biotinylated antibody or 10 µg/ml of Anti-Human IL-1β biotinylated were used as detection antibodies 
and incubated for 15 min and 10 min, respectively. EA-HRP in a concentration of 4 µg/ml was incubated 
for further 15 min in coated MCF strips #1 and #2 and for 10 min in strip #3. The enzyme used in strip #4 
(IL-1β assay) was High Sensitivity Streptavidin–HRP with 4 µg/ml, incubated for 10 min. Three washing 
steps were performed afterwards. Subsequently, 1 mg/ml of OPD and 1 mg/ml H2O2 (equivalent to molar 
ratio 1:3) solution was added to strip #1 (PSA assay) and #3 (IL-1β assay) and 4 mg/ml of OPD and 1 
mg/ml H2O2 (molar ratio 1:1) were added to strips #2 (PSA assay) and #4 (IL-1β assay). The MCF strips 
were scanned as RGB images with a HP ScanJet G4050 (Hewlett-Packard, CA, USA) flatbed scanner at 
2,400 dpi resolution in transmittance mode in intervals of 2–3 min over 30 min of incubation.  
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2.5 Optical interrogation of MCF strips 
For quantitation of colorimetric signal in the microcapillaries, RGB digital images were split into 3 
separated channels in Image J (NIH, USA). The blue channel images were used to calculate absorbance 
values, based on the grey scale peak height of each individual capillary of FEP-Teflon MCF as described 
elsewhere.[16–18] Absorbance (Abs) was calculated for each individual capillary based on equation (1): 
Abs =  −log10(
𝐼
𝐼0
) 
 (1) 
where I is the grey scale peak height (transmitted light intensity) and I0 is the maximum grey scale value. 
The absorbance values were averaged across 10 capillaries for MCF strip. 
 
3. RESULTS AND DISCUSSION 
We believe enzymatic conversion using off-the-shelf chromogenic substrates is a solution for the well 
desirable portability, sensitivity and affordability of POC tests for optical detection of protein biomarkers 
in the nanomolar to femtomolar range, which represents the core of clinical diagnostics market. However, 
a key aspect that remains clearly underexplored in miniaturized ELISA tests is the kinetics of enzymatic 
substrates conversion, which perhaps is the most crucial yet powerful step in a colorimetric or fluorescence 
ELISA. OPD (MW=108.1 g/mol) is widely used as a HRP chromogenic substrate by the biggest 
worldwide manufacturers and suppliers of bioanalytical reagents to life sciences laboratories, and typically 
recommend 0.4 mg/ml of OPD and 0.4 mg/ml of H2O2 (MW=34.0 g/mol) or 0.5-1 mg/ml of OPD and 0.3 
mg/ml of H2O2. Nevertheless, datasheets are usually not detailed enough regarding the OPD:H2O2 molar 
ratio, which is of paramount importance for ELISA detection in miniaturized tests designed to be optically 
interrogated with less sophisticated readout systems.  
In order to optimize OPD enzymatic conversion in our novel ELISA microfluidic platform[17] which 
used in this study a flatbed scanner for signal readout, we analyzed the stoichiometry of HRP conversion 
of OPD to 2,3-diaminophenazine (DAP) (Fig. 2A), realizing that two molecules of OPD and one of 
hydrogen peroxidase (H2O2) are necessary for the enzyme to be able to convert OPD (colorless) into DAP 
(brownish color), which yields a theoretical optimal molar ratio of 2:1. The concentrations of 0.4 mg/ml 
for both OPD and H2O2 as recommended by the suppliers yield a molar ratio of 1:3 for OPD:H2O2 in 
sandwich ELISA assays which, according to Nicell et al.[36] has an inhibitory effect in HRP catalytic 
activity by H2O2.  
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We compared initially the chromogenic sensitivity and dynamic range of a flatbed scanner in respect 
to DAP detection against a conventional bench-top microplate reader (Fig. 2B). The microplate based 
detection of DAP was about 256 times more sensitive (0.244 pg/ml) than in a 10-bore MCF produced 
from Teflon-FEP with a flatbed scanner (62.5 pg/ml). This links to the much shorter light path distance of 
200 µm microcapillaries compared to 3mm light path distance is a microwell. We noticed, however, 
the DAP scanning in the MCF presented a much broader dynamic range, equivalent to 5% to 100% of 
OPD conversion, whereas the dynamic range for microwell is limited to the range of 0.02%-15% 
conversion. Despite DAP being more sensitive in a microwell plate, it lacks quantitation capability for 
high rates of OPD conversion, whereas in the small microcapillaries the Lambert-Beer law is valid on a 
very broad range of equivalent OPD substrate concentrations. We hypothesized therefore that substrate 
concentration should be dramatically increased in order to achieve much faster and more sensitive 
immunoassays, should HRP be capable of handling such high concentrations of OPD and/or H2O2. 
Consequently, we tested the effect of both OPD and H2O2 concentration in the presence of a constant 
solubilized ExtraAvidin-HRP (EA-HRP) concentration and noticed HRP conversion of OPD in the 
commercial formulations is characterized by an inhibition by H2O2 (Fig. 2C and 2D). 
The initial rates of OPD conversion, -rs increased with increasing concentration of H2O2 (inhibitor, 
[I]) up to a value of 0.5-1.0 mg/ml (Fig. 2C), beyond which the initial conversion rate started decreasing. 
This enzymatic behavior is coherent with inhibition by substrate, in this case H2O2, and Haldane 
model[37] mathematically described by equation (2) has shown the lower value for the sum of the squared 
difference between experimental and model predicted data thus being the best-fitted model in this case:  
 
−𝑟𝑠 = −𝑟𝑚𝑎𝑥
[𝐼]
𝐾𝑠 + [𝐼] +
[𝐼]2
𝐾𝑖
 
 (2) 
 
 
This experiment also allowed determining the ideal concentration of both OPD and H2O2, which were 
4 mg/ml and 1 mg/ml, respectively, i.e. equivalent to a OPD:H2O2 molar ratio of 1:1. Fitting the substrate 
enzymatic inhibition model in equation (2) a value of 0.07 mg/ml and 0.91 mg/ml were obtained for 
inhibition constant, Ki with 1.0 mg/ml and 4.0 mg/ml of OPD respectively, indicating a higher degree of 
enzyme inhibition with the use of lower OPD concentration. With a OPD:H2O2 molar ratio of 1:3 used in 
commercial OPD substrates, the value of –rs obtained was 0.11 mg/ml.s whereas with 1:1 molar ratio a 
maximum –rs value of 0.191 mg/ml.s was obtained which represented a 1.7-fold increase. But the overall 
impact of using a suboptimum OPD:H2O2 molar ratio is much bigger than this value, as there are also 
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direct implications on substrate depletion and diffusion, limiting the rate of enzymatic conversion which 
is linked to the development of optical signal. 
In Fig. 2D the impact of OPD:H2O2 molar ratio is further elucidated. In this experimental set the 
concentrations were changed for both OPD and H2O2 in order to keep initial OPD:H2O2 molar ratio 
constant. This revealed OPD substrate was not responsible for the inhibition, with the values of –rs 
increasing as a first order kinetic model for low concentration of OPD and clearly trending to a zero order 
for higher concentrations of substrate, which is typical of a non-competitive or mixed inhibition kinetic 
model, mathematically described in equation (3).[38]. Hence, a significant higher conversation rate for 
reaction with molar ratio 1:1 of OPD/H2O2 is disclosed, which for data points of 1 mg/ml of OPD shows 
a 2-fold increase in enzymatic conversion rate.  
 
−𝑟𝑠 = −𝑟𝑆,𝑚𝑎𝑥
[𝑆]
𝛼𝐾𝑚 + 𝛼′[𝑆]
 
       (3) 
 
where Ki and Ki’ are the inhibitor constants representing the inhibition effects and are described below, in 
equations (4) to (7): 
𝛼 = 1 +
[𝐼]
𝐾𝑖
 
 (4) 
𝛼′ = 1 +
[𝐼]
𝐾𝑖
′ 
 
  (5) 
𝐾𝑖 =
[𝐸][𝐼]
[𝐸𝐼]
 
 (6) 
𝐾𝑖
′ =
[𝐸𝑆][𝐼]
[𝐸𝑆𝐼]
 
 (7) 
 
The kinetic model in equations (3) to (7) considers the inhibitor can bind the enzyme or the enzyme-
substrate complex reducing the overall enzyme activity. The kinetic model parameters were found by best-
fitting the model to the experimental data using Solver tool in Excel, and are summarized in Table 1. 
These revealed a significant difference in the maximum rate of substrate conversion, -rs,max shown in Fig. 
2D, representing a 3.2-fold increase in maximum rate of conversion of OPD. 
It is clear from data in Table 1 that the inhibition has higher impact on enzyme kinetics at a molar ratio 
of 1:3. As previously discussed, Km remained approximately constant at both molar ratios tested, with the 
value of -rs,max being strongly affected by the molar ratio. This reinforces the non-competitive inhibition 
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model typical of HRP.[38] Based on equation (6) and (7) the smaller the values of both Ki and Ki’, the 
more efficient is the inhibitor binding either the enzyme itself or the enzyme-substrate-inhibitor complex. 
Comparing the two curves in Fig. 2D, Ki at 1:1 molar ratio was about 280 times higher than the value of 
Ki at 1:3 molar ratio, suggesting the inhibitor, I (in this case H2O2) binds directly to the enzyme. For 1:3 
molar ratio, the value of Ki obtained was very similar to that of Ki’, which again is typical of a non-
competitive inhibition,[38] where the reaction is only inhibited by the formation of enzyme-inhibitor 
complex.  
Overall, it appeared that when in excess H2O2 inhibits HRP enzymatic kinetics by reducing the enzyme 
activity, however it does not affect the affinity of HRP to the substrate. This inhibition effect is surpassed 
by deviating from the molar ratio initially recommended by the manufacturers, i.e. 1:3 to 1:1. 
Although molar ratio of OPD:H2O2 revealed paramount to the rate of generation of colorimetric signal 
by affecting HRP kinetics, the diffusion and mass transfer limitations need to be taken into account in 
respect to the speed and magnitude of colorimetric signal produced, which ultimately controls both speed 
and sensitivity of the immunoassay. In heterogeneous immunoassays the enzyme is immobilized on the 
surface and consequently the kinetics of substrate conversion is modified because of mass transfer 
limitations. Immobilized enzyme reactions present lower initial velocities, due to migration time of 
substrate molecules to the walls and to possible conformational changes during adsorption or binding 
process.[39] This is the typical situation in a microtiter plate, where the maximum distance of molecular 
diffusion is in the range of 3 mm, which can represent several minutes for a medium size molecule. Further 
experiments with solubilized enzyme in a microwell (Fig. 3A) confirmed the increase in the rate of 
colorimetric signal generation with the increase of OPD concentration. Nevertheless, experiments with 
immobilized enzyme (Fig. 3B) revealed not being advantageous to use higher rates of conversion of OPD 
as this leads to the rapid accumulation of product near the plastic wall and fluctuations in the rate of 
conversion of OPD which is not beneficial for immunoassays, where typically the end-point or kinetics 
rate is expected to be linked to the concentration of analyte in the sample. The absorbance values obtained 
were lower than those for solubilized enzyme as, in one hand, the enzyme immobilization process might 
interfere with enzyme catalytic activity[40] and, on the other hand, the total enzyme molecules available 
are dependent on the quantity of molecules bound to the wall. We estimated the turnover number of the 
HRP enzyme in this specific system by analyzing the velocity rates with the changing of enzyme 
concentration and, assuming that ExtrAvidin contains two molecules of peroxidase, a values of 1.95x106 
s-1 was obtained. 
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In miniaturized ELISA platforms such as MCF, diffusion distances are very short and, consequently, 
an increase in conversion rates of substrate is beneficial. With a maximum diffusion distance of 100 µm, 
substrate conversion with HRP will approach the situation shown in Fig. 3A for solubilized enzyme, which 
ultimately translate into stronger colorimetric signal generated with much shorter incubation times. This 
feature enhances the signal-to-noise ratios and ultimately improves sensitivity of the assay, assuming the 
enzyme is working at maximum ‘capacity’ (activity). Note that when using EA-HRP in a sandwich 
ELISA, it is known that extravidin binds to the biotinylated antibody, eliminating the problem of catalytic 
enzymatic activity reduction due to its conformational change. 
To illustrate the multiple benefits of the 1:1 molar ratio for OPD:H2O2 and higher initial OPD 
concentration we carried out multiple PSA and IL-1β sandwich ELISAs optimized for the MCF. Fig. 4 
shows the effect of OPD incubation on the performance of these two assays. The incubation time required 
for PSA detection was reduced in 10-fold when compared to the conventional 1:3 molar ratio, and both 
the signal and sensitivity (or lower limit of detection defined as absorbance of blank plus three standard 
deviations) were improved from 11.5 to 0.7 ng/ml (i.e. 16x reduction in detection limit). In the case of 
human IL-1β quantitation the limit of detection was also further improved from 100 to 6 pg/ml. The rate 
of OPD enzymatic conversion also revealed much faster as the signal obtained with just 3 minutes of OPD 
incubation was about 3-fold stronger than the signal obtained with 30 minutes OPD incubation with 1:3 
molar ratio.  
 
CONCLUSIONS 
HRP conversion of a common chromogenic substrate, OPD in a microfluidic device was characterized 
by H2O2 inhibition of enzyme activity, leading to extended incubation times and weak colorimetric signals 
difficult to detect with less sophisticated optoelectronic components. By increasing the initial OPD 
concentration from 1.0 to 4.0 mg/ml and OPD:H2O2 molar ratio from 1:3 to 1:1 the value rate of enzymatic 
conversion was increased by 2-fold, which revealed very beneficial for microfluidic devices that contain 
short diffusion distances. It also avoided the rapid depletion of substrate that characterizes commercial 
OPD formulations. A number of sandwich assays with PSA and IL-1β detection in fluoropolymer 
microfluidic MCF strips and a flatbed scanner showed systematically above one order of magnitude 
increase in sensitivity and/or speed of the assay. This allows mimicking the performance and reliability of 
sophisticated laboratory detection equipment using low-cost optoelectronic equipment, which is expected 
to trigger the development of affordable POC tests that fully exploit the low-cost and unique amplification 
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capabilities of enzymatic ELISA detection with ubiquitous optical detection technologies like 
smartphones and flatbed scanners.  This change in enzymatic substrate molar ratio can be applied to all 
miniaturized ELISA tests, opening the possibility for a new generation of affordable optical microfluidic 
POC diagnostic tests.  
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Table 1. Kinetic parameters (non-competitive/mixed inhibition) for the two different molar ratios of 
OPD:H2O2 studied 
 1:3 OPD:H2O2 1:1 OPD:H2O2 
-rs,max (mg/ml.s) 0.50 1.61 
Km (mg/ml) 8.39 8.39 
Ki (mg/ml) 5.53 1561.00 
Ki’ (mg/ml) 5.32 0.39 
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Figure captions 
Fig. 1 Miniaturized enzymatic assays. (A) Our concept of miniaturized enzymatic assays - immobilized 
enzymes present similar conversion kinetics to enzymes in solutions, due to small diffusion distance. (B): 
Microcapillary Film (MCF) - (i) MCF reel (ii) photography of MCF with blue dye inside the 200 µm 
diameter capillaries. (C) Aspiration of solutions in the microfluidic MCF strips using a 1 ml syringe.  
 
Fig. 2 Aspects of colorimetric detection in MCF and peroxidase inhibition. (A) HRP conversion of OPD 
chromogenic substrate. (B) Response curves for detection of DAP (colored product) in a miniaturized 
MCF with a flatbed scanner and in a 96 MTP using a microplate reader. Absorbance values have been 
normalized by the light path of MCF (0.02 cm) and MTP (0.3 cm) respectively. (C) Initial enzymatic 
conversion rates for different molar ratios of OPD and H2O2. (D) Initial conversion rates of OPD as 
function of H2O2 and OPD concentration. The concentration of EA-HRP was kept constant at 15.6 ng/ml. 
 
Fig. 3 Kinetics of HRP conversion of OPD for varying concentration of chromogenic substrate. (A) EA-
HRP in solution. (B) EA-HRP immobilized on plastic surface of a 96 microtiter plate well. Concentration 
of H2O2 was kept constant at 1 mg/ml H2O2, as the molar ratio of 1:3 OPD/H2O2, and final concentration 
of EA-HRP immobilized or in solution was kept at 15.6 ng/ml. 
 
Fig. 4 Comparison between two different OPD and H2O2 molar ratio in MCF sandwich assays. (A) 4 
mg/ml of OPD and 1 mg/ml of H2O2 (1:3 molar ratio) makes the PSA MCF assay 10 times faster and with 
16x higher sensitivity. (B) IL-1β assay improved sensitivity from 100 pg/ml to 6 pg/ml with 3-fold 
reduction in assay time. The times shown relate only to the time of incubation of OPD before optical 
interrogation of the microfluidic MCF strips.♦ 1:1 molar ratio OPD:H2O2 and ●1:3 molar ratio OPD:H2O2. 
Absorbance values have been normalized by the maximum light path distance in the MCF (i.e. 0.02 cm) 
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